MYDA Advisors LLC Purchases 13,000 Shares of Affimed (NASDAQ:AFMD)

MYDA Advisors LLC grew its position in shares of Affimed (NASDAQ:AFMDGet Rating) by 19.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,000 shares of the biopharmaceutical company’s stock after buying an additional 13,000 shares during the period. MYDA Advisors LLC owned approximately 0.08% of Affimed worth $442,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Affimed by 0.7% during the 3rd quarter. BlackRock Inc. now owns 6,778,090 shares of the biopharmaceutical company’s stock worth $41,889,000 after purchasing an additional 44,153 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Affimed by 14.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 6,122,651 shares of the biopharmaceutical company’s stock worth $37,838,000 after purchasing an additional 786,748 shares in the last quarter. 683 Capital Management LLC grew its holdings in shares of Affimed by 6.4% during the 3rd quarter. 683 Capital Management LLC now owns 5,602,313 shares of the biopharmaceutical company’s stock worth $34,622,000 after purchasing an additional 337,313 shares in the last quarter. Pictet Asset Management SA grew its holdings in shares of Affimed by 15.9% during the 4th quarter. Pictet Asset Management SA now owns 4,627,458 shares of the biopharmaceutical company’s stock worth $25,544,000 after purchasing an additional 636,342 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Affimed by 47.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,846,200 shares of the biopharmaceutical company’s stock worth $17,590,000 after purchasing an additional 916,189 shares in the last quarter. Hedge funds and other institutional investors own 63.47% of the company’s stock.

Several analysts have recently issued reports on AFMD shares. StockNews.com lowered Affimed from a “hold” rating to a “sell” rating in a report on Monday, March 28th. Cantor Fitzgerald initiated coverage on Affimed in a research note on Wednesday, February 23rd. They issued an “overweight” rating and a $12.00 price objective on the stock. Piper Sandler initiated coverage on Affimed in a research note on Wednesday, March 30th. They issued an “overweight” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research raised Affimed from a “sell” rating to a “hold” rating in a research note on Tuesday, April 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.17.

Shares of AFMD stock traded down $0.10 during mid-day trading on Wednesday, reaching $3.41. 17,657 shares of the stock traded hands, compared to its average volume of 1,813,907. The stock’s fifty day simple moving average is $4.08 and its two-hundred day simple moving average is $4.85. Affimed has a 1-year low of $2.88 and a 1-year high of $9.82. The company has a market cap of $420.86 million, a price-to-earnings ratio of -6.16 and a beta of 2.49. The company has a quick ratio of 3.19, a current ratio of 3.20 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMDGet Rating) last announced its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Affimed had a negative net margin of 149.76% and a negative return on equity of 40.66%. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.30 million. During the same period in the previous year, the business posted ($0.20) earnings per share. On average, equities research analysts anticipate that Affimed will post -0.79 EPS for the current fiscal year.

About Affimed (Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Featured Stories

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed (NASDAQ:AFMDGet Rating).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.